MYC and prostate carcinoma: <h4>Objectives</h4>Through a genomics-based approach analyzing gene expression levels and adaptive immune receptor recombinations, we sought to determine whether MYC amplification was associated with a worse outcome and reduced immunogenicity.<h4>Methods</h4>MYC copy numbers and the presence of adaptive immune receptor (IR) recombination sequencing reads were quantified in genomics files representing prostate cancer samples.<h4>Results</h4>Our results showed that increased MYC amplification was found in metastatic stages of prostate cancer.